uuid:
  -
    value: 7b8305fa-d967-43fc-8a7e-6c5a7dfaf3a3
langcode:
  -
    value: und
type:
  -
    target_id: case_series
    target_type: node_type
    target_uuid: 0ea0fe3a-e616-4d45-88b7-f6bb126fd852
revision_timestamp:
  -
    value: '2016-07-19T17:33:52+00:00'
    format: 'Y-m-d\TH:i:sP'
revision_uid:
  -
    target_type: user
    target_uuid: 7f2b027c-635a-47bd-9500-94902c2d3670
revision_log: {  }
status:
  -
    value: true
uid:
  -
    target_type: user
    target_uuid: 7f2b027c-635a-47bd-9500-94902c2d3670
title:
  -
    value: 'Elan and Royalty Pharma'
created:
  -
    value: '2016-07-16T00:26:00+00:00'
    format: 'Y-m-d\TH:i:sP'
changed:
  -
    value: '2016-07-19T17:33:52+00:00'
    format: 'Y-m-d\TH:i:sP'
promote:
  -
    value: false
sticky:
  -
    value: false
default_langcode:
  -
    value: true
revision_translation_affected:
  -
    value: true
path:
  -
    alias: /faculty-and-research/case-series/id/a06-13-0021
body:
  -
    value: '<p><span>In June 2013, Elan’s shareholders (Elan Corporation, NYSE: ELN) were faced with a difficult choice. Elan’s management had four proposals on the table, management’s attempt to defend itself against a hostile takeover from Royalty Pharma. Royalty Pharma was a private company, a private equity-owned collector of biotech and pharmaceutical royalties. If shareholders voted in favor of any of the four initiatives, it would likely kill Royalty Pharma’s offer—and its guaranteed returns. That would allow Elan to stay independent, and remain under the control of a management team generally considered as underperforming.</span></p>'
    format: basic_html
    processed: ''
    summary: ''
    summary_processed: ''
field_case_number:
  -
    value: A06-13-0021
field_case_page_length:
  -
    value: '14 pages'
field_case_series_author:
  -
    target_type: taxonomy_term
    target_uuid: 9b4ad240-d748-42b9-ae24-15871020bcfa
field_case_series_date: {  }
field_case_series_image: {  }
field_case_series_industry:
  -
    target_type: taxonomy_term
    target_uuid: 13096043-8dd0-4a05-ae37-8f09da97fdae
field_case_series_year:
  -
    value: '2013-01-01'
field_case_setting:
  -
    value: Ireland
field_case_source:
  -
    value: Library
field_case_subject: {  }
field_fields:
  -
    target_type: taxonomy_term
    target_uuid: bd8c2f59-a006-4b52-9ba5-aeb56c1427ac
field_teaching:
  -
    value: 'This case has been used in both MBA and Executive Education programs to examine the process and valuation of potential acquisitions and the basic use of discounted cash flow analysis. The case allows a narrowly defined valuation debate using traditional discounted cash flow valuation techniques, combined with a wider scope of corporate strategy and future value creation.'
_content_sync:
  entity_type: node
  entity_dependencies:
    user:
      - user.user.7f2b027c-635a-47bd-9500-94902c2d3670
    taxonomy_term:
      - taxonomy_term.case_series_authors.9b4ad240-d748-42b9-ae24-15871020bcfa
      - taxonomy_term.case_series_industry.13096043-8dd0-4a05-ae37-8f09da97fdae
      - taxonomy_term.case_series_fields.bd8c2f59-a006-4b52-9ba5-aeb56c1427ac
